Despite relatively higher rates of dementia among Indigenous populations internationally, research into drivers of disparities in brain health and cognitive function has tended to focus on modifiable risk factors over cultural understandings and contextual determinants. By seeking to characterize social and cultural factors that shape brain health and cognition in Indigenous populations, this mini scoping review expands prevailing schools of thought to include Indigenous knowledge systems. This reveals important gaps in culturally aligned care. It also reclaims horizons for research important to Indigenous Peoples that have garnered diminished attention in biomedical approaches. Twenty-three sources were included for data extraction. This synthesis of 23 sources includes health communication about dementia, health provider knowledge about Indigenous health, culturally relevant screening and assessment tools, and culturally grounded care models. Much of the focus is currently still on modifiable risk factors that reside at individual factors, whereas attention to wider social factors that impact populations is needed, as stressors through isolation, discrimination, and unequal care are widely reported. Going forward, identifying structural barriers to living well and recognizing the importance of connection to culture will benefit both Indigenous and non-Indigenous understandings of brain health.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10903363PMC
http://dx.doi.org/10.3389/fpubh.2024.1346753DOI Listing

Publication Analysis

Top Keywords

brain health
16
indigenous peoples
8
indigenous populations
8
modifiable risk
8
risk factors
8
health
7
indigenous
7
factors
5
colonial drivers
4
drivers cultural
4

Similar Publications

Article Synopsis
  • A study evaluated the impacts of divalproex sodium on brain volumes in patients with mild to moderate Alzheimer’s disease using MRI scans over 24 months.
  • The results indicated that participants receiving divalproex experienced a significantly higher decline in hippocampal and brain volumes compared to those on placebo, along with a faster decline in cognitive function as measured by the Mini-Mental State Examination.
  • The findings suggest that divalproex treatment is linked to accelerated brain volume loss and potentially increased cognitive impairment, although the long-term effects remain unclear.
View Article and Find Full Text PDF
Article Synopsis
  • The study tested whether divalproex sodium (valproate) could prevent or delay agitation and psychosis in individuals with moderate Alzheimer's disease, enrolling 313 participants.
  • After two years of treatment, results showed no significant difference between the valproate and placebo groups regarding the time to development of agitation or psychosis.
  • Additionally, the valproate group experienced more side effects and showed greater reductions in brain volume, indicating potential adverse effects of the treatment.
View Article and Find Full Text PDF

Objective: To delineate the trajectories of Aβ42 level in cerebrospinal fluid (CSF), fludeoxyglucose F18 (FDG) uptake using positron emission tomography, and hippocampal volume using magnetic resonance imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD).

Design: Cohort study.

Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!